Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41586-020-2622-0 http://scihub22266oqcxt.onion/10.1038/s41586-020-2622-0 32756549!7581537!32756549     free     free     free Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nature 2020 ; 586 (7830): 567-571 Nephropedia Template TP {{tp|p=32756549|t=2020. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness |pdf=|usr=}}{{32756549}} gab.com Text SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness JO: Nature http://www.kidney.de/pget.php?&tw=1&pmid=32756549 #FOAvip A vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to control the coronavirus disease 2019 (COVID-19) global pandemic. Structural studies have led to the development of mutations that stabilize Betacoronavirus spike proteins in the prefusion state, improving their expression and increasing immunogenicity(1). This principle has been applied to design mRNA-1273, an mRNA vaccine that encodes a SARS-CoV-2 spike protein that is stabilized in the prefusion conformation. Here we show that mRNA-1273 induces potent neutralizing antibody responses to both wild-type (D614) and D614G mutant(2) SARS-CoV-2 as well as CD8(+) T cell responses, and protects against SARS-CoV-2 infection in the lungs and noses of mice without evidence of immunopathology. mRNA-1273 is currently in a phase III trial to evaluate its efficacy. Twit Text FOAVip SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness ????Nature http://www.kidney.de/pget.php?&tw=1&pmid=32756549 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32756549 #FOAvip English Wikipedia <ref>{{Cite pmid|32756549}}</ref> SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness #MMPMID32756549 Corbett KS; Edwards DK; Leist SR; Abiona OM; Boyoglu-Barnum S; Gillespie RA; Himansu S; Schafer A; Ziwawo CT; DiPiazza AT; Dinnon KH; Elbashir SM; Shaw CA; Woods A; Fritch EJ; Martinez DR; Bock KW; Minai M; Nagata BM; Hutchinson GB; Wu K; Henry C; Bahl K; Garcia-Dominguez D; Ma L; Renzi I; Kong WP; Schmidt SD; Wang L; Zhang Y; Phung E; Chang LA; Loomis RJ; Altaras NE; Narayanan E; Metkar M; Presnyak V; Liu C; Louder MK; Shi W; Leung K; Yang ES; West A; Gully KL; Stevens LJ; Wang N; Wrapp D; Doria-Rose NA; Stewart-Jones G; Bennett H; Alvarado GS; Nason MC; Ruckwardt TJ; McLellan JS; Denison MR; Chappell JD; Moore IN; Morabito KM; Mascola JR; Baric RS; Carfi A; Graham BS Nature 2020[Oct]; 586 (7830): 567-571 PMID32756549show ga A vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to control the coronavirus disease 2019 (COVID-19) global pandemic. Structural studies have led to the development of mutations that stabilize Betacoronavirus spike proteins in the prefusion state, improving their expression and increasing immunogenicity(1). This principle has been applied to design mRNA-1273, an mRNA vaccine that encodes a SARS-CoV-2 spike protein that is stabilized in the prefusion conformation. Here we show that mRNA-1273 induces potent neutralizing antibody responses to both wild-type (D614) and D614G mutant(2) SARS-CoV-2 as well as CD8(+) T cell responses, and protects against SARS-CoV-2 infection in the lungs and noses of mice without evidence of immunopathology. mRNA-1273 is currently in a phase III trial to evaluate its efficacy. |2019-nCoV Vaccine mRNA-1273[MESH] |Animals[MESH] |Antibodies, Neutralizing/immunology[MESH] |Betacoronavirus/genetics/*immunology[MESH] |CD8-Positive T-Lymphocytes/immunology[MESH] |COVID-19[MESH] |COVID-19 Vaccines[MESH] |Clinical Trials, Phase III as Topic[MESH] |Coronavirus Infections/genetics/*immunology/*prevention & control/virology[MESH] |Female[MESH] |Lung/immunology/virology[MESH] |Mice[MESH] |Mutation[MESH] |Nose/immunology/virology[MESH] |Pandemics/*prevention & control[MESH] |Pneumonia, Viral/*immunology/*prevention & control/virology[MESH] |RNA, Messenger/genetics[MESH] |RNA, Viral/genetics[MESH] |SARS-CoV-2[MESH] |Th1 Cells/immunology[MESH] |Toll-Like Receptor 4/agonists/immunology[MESH]SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedn(epmc).pdf DeepDyve Pubget Overpricing